

DEPOSITARY RECEIPTS

NEW DR ANNOUNCEMENT

June 16, 2015

Biotie Therapies Corp

Biotie Therapies is a specialized drug development company based in Finland. The Company is focused on the development of drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease, Alzheimer's disease and other cognitive disorders, bipolar disorder, addictions and drug dependence) and inflammatory diseases (rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease and others). The Company has several innovative small molecule and biological drug candidates at different stages of clinical development. The Company's products address diseases with high unmet medical need and significant market potential.

Effective Date:	June 16, 2015
Country of Incorporation:	Finland
Exchange:	NASDAQ Stock Market
Type of ADR Program:	Sponsored - Level III
Ticker Symbol:	BITI
CUSIP Number:	09074D103
Ratio (DR:ORD):	1 : 80
Underlying Share Description:	Ordinary
Industry Classification:	Pharma. & Biotech.
Custodian(s) :	Nordea Bank Finland Plc

To learn more about ADRs and issuer programs, please call our marketing desks:

New York

Ravi Davis
Adrdesk@bnymellon.com
Tel: 212 815 2267

Hong Kong

Herston Powers
Vice President
herston.powers@bnymellon.com
Tel: 852 2840 9868

London

Damon Rowan
Vice President
damon.rowan@bnymellon.com
Tel: 442071637511

Depository Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contained herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.